Prenatal screening
G-NIPT® Basic
Screening for trisomy 21, 18, and 13; sex chromosome aneuploidies; fetal sex confirmation; and other autosomal trisomies.
- Lab
- 3billion
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 10–12 days
Clinical test menu
Tests categorized by clinical use case.
Browse AC testing pathways by indication rather than by laboratory catalog: prenatal screening, oncology, hemato-oncology, hereditary cancer, rare disease, reproductive genetics, preventive genomics, and wellness-oriented tests.
Tests are intended to be ordered and interpreted in consultation with a qualified physician. Turnaround times are indicative and may vary by specimen quality, shipment timing, and reference laboratory workflow.
Menu overview
40
listed tests
8
categories
Prenatal ScreeningPrecision Oncology — Solid TumorHematologic OncologyHereditary CancerRare Disease Genomics
40 tests shown
5 tests
Prenatal Screening
NIPT and non-invasive prenatal screening options from maternal blood.
Prenatal screening
AC-NIP-BASIC
Prenatal screening
G-NIPT® Lite
Core non-invasive prenatal screening for trisomy 21, 18, and 13, sex chromosome aneuploidies, and fetal sex confirmation.
- Lab
- 3billion
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 10–12 days
Prenatal screening
G-NIPT® Premium
Expanded NIPT covering all autosomes, sex chromosome aneuploidies, fetal sex, selected CNVs, and CNVs larger than 7 Mb.
- Lab
- 3billion
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 10–12 days
Prenatal screening
i-screen®
Non-invasive prenatal screening option performed from maternal EDTA whole blood.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- 10–12 days
Prenatal screening
NICE® Premium + Pathogen
Expanded NIPT with all autosomes, sex chromosome aneuploidies, 143 microdeletions, fetal sex, and a focused pathogen panel.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 10–12 days
4 tests
Precision Oncology — Solid Tumor
Tumor profiling, HRD, and liquid biopsy pathways for solid cancers.
Tumor profiling
Tumor profiling
Solid Tumor — FFPE / Biopsy (+RNA)
Comprehensive solid tumor profiling including hotspot mutations, full-exon coverage, CNV, RNA fusion analysis, MSI, and TMB.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- FFPE tissue
- TAT
- 17–21 days
Tumor profiling
Solid Tumor — FFPE / Biopsy (excl. RNA)
DNA-focused solid tumor profiling from FFPE tissue when RNA analysis is not required or not feasible.
- Lab
- GC Genome
- Specimen
- FFPE tissue
Tumor profiling
Solid Tumor Liquid Biopsy (cfDNA)
cfDNA tumor profiling covering point mutations, CNVs, and selected RNA fusions.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 12–14 days
Tumor profiling
GreenPlan® HRD
Homologous recombination deficiency testing from tumor tissue.
- Lab
- 3billion
- Specimen
- FFPE tissue
5 tests
Hematologic Oncology
NGS panels for acute leukemia, lymphoma, MDS/MPN, and plasma-cell neoplasms.
Hematologic malignancy
Hematologic malignancy
ALL Panel
Molecular profiling panel for acute lymphoblastic leukemia.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood / bone marrow
- TAT
- 12–14 days
Hematologic malignancy
AML Panel
Molecular profiling panel for acute myeloid leukemia and related clinical questions.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood / bone marrow
- TAT
- 12–14 days
Hematologic malignancy
Lymphoma Panel
A 60-gene panel for molecular characterization of lymphoid malignancies.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood / bone marrow
- TAT
- 12–14 days
Hematologic malignancy
MDS / MPN Panel
Molecular profiling for myelodysplastic and myeloproliferative neoplasms.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood / bone marrow
- TAT
- 12–14 days
Hematologic malignancy
Multiple Myeloma Panel
Molecular testing panel for plasma-cell neoplasms.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood / bone marrow
- TAT
- 12–14 days
2 tests
Hereditary Cancer
Germline cancer predisposition testing and family-risk assessment.
Hereditary cancer
Hereditary cancer
Hereditary Cancer Panel (98 genes)
A 98-gene germline panel covering inherited cancer predisposition across 23 cancer types.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- 17–21 days
Hereditary cancer
Hereditary Women's Cancer Panel
Focused hereditary cancer panel for breast, ovarian, and other women's cancer risk indications.
- Lab
- GC Genome
- Specimen
- EDTA whole blood
9 tests
Rare Disease Genomics
Exome, genome, and targeted testing for rare or undiagnosed disease.
Exome / genome sequencingTargeted rare disease
Exome / genome sequencing
DGS — Proband
Diagnostic genome sequencing for a proband with suspected rare or undiagnosed genetic disease.
- Lab
- 3billion
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~65 days
Exome / genome sequencing
DGS — Trio
Trio-based diagnostic genome sequencing for rare disease evaluation.
- Lab
- 3billion
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~65 days
Targeted rare disease
Family Test (Sanger)
Targeted familial variant testing using Sanger sequencing.
- Method
- Sanger
- Specimen
- EDTA whole blood / amniotic fluid
Targeted rare disease
Fragile-X Screening
FMR1 repeat-expansion screening for Fragile X syndrome indications.
- Method
- Fragment analysis
- Specimen
- EDTA whole blood
- TAT
- ~12 days
Targeted rare disease
SMA — SMN1/SMN2 del/dup (MLPA)
SMN1/SMN2 dosage analysis for spinal muscular atrophy.
- Method
- MLPA
- Specimen
- EDTA whole blood
- TAT
- 21–30 days
Exome / genome sequencing
WES — Proband (3 Billion)
Whole exome sequencing for a proband with suspected rare genetic disease.
- Lab
- 3billion
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~30 days
Exome / genome sequencing
WES — Proband (GC Genome)
Whole exome sequencing through GC Genome for proband-only evaluation.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~30 days
Exome / genome sequencing
WES — Trio (GC Genome)
Trio whole exome sequencing through GC Genome.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~30 days
Exome / genome sequencing
Whole Genome Sequencing (3 Billion)
Whole genome sequencing for broad rare disease assessment.
- Lab
- 3billion
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- ~30 days
3 tests
Reproductive & Chromosomal
Chromosomal microarray and reproductive genetic testing pathways.
Chromosomal analysisHematologic malignancy
Chromosomal analysis
Bebegene Extended (1001 Microdeletions)
SNP microarray covering hundreds of chromosomal abnormalities and 1001 microdeletions/duplications.
- Lab
- 3billion
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- 10–14 days
Chromosomal analysis
Chromosomal Microarray — EDGC (CMA)
Chromosomal microarray for developmental delay, autism spectrum disorder, congenital anomalies, and related indications.
- Lab
- EDGC
- Method
- SNP microarray
- Specimen
- EDTA blood / gDNA / amniotic fluid
- TAT
- 12–18 days
Hematologic malignancy
Pregnancy Loss (All Chromosome, NGS)
All-chromosome deletion/duplication analysis for products of conception and pregnancy loss evaluation.
- Lab
- EDGC
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 10–12 days
7 tests
Preventive & Pharmacogenomics
Predictive health screening, pharmacogenetics, and disease-risk genomics.
Cancer early detectionPreventive genomicsPharmacogenetics
Cancer early detection
ai-CANCERCH®
Multi-cancer early detection from cfDNA; includes five cancer types for males and six cancer types for females, including ovarian cancer.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- Streck cfDNA tube
- TAT
- 14–21 days
Preventive genomics
Genome Health (Female)
Polygenic risk assessment across 45 disease categories for females, including 14 cancer types.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Preventive genomics
Genome Health (Male)
Polygenic risk assessment across 44 disease categories for males, including neurological, cardiovascular, metabolic, and cancer risks.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Preventive genomics
Genome Screen — Cancer
Genomic screening focused on inherited cancer predisposition and risk stratification.
- Lab
- GC Genome
- Specimen
- EDTA whole blood
Preventive genomics
Genome Screen — Cardiac Arrest
A 40-gene screen covering 15 disease types, including hereditary arrhythmia syndromes.
- Lab
- GC Genome
- Method
- NGS
- Specimen
- EDTA whole blood
- TAT
- 17–21 days
Pharmacogenetics
Pharmacogenetics (34 drugs)
Ten-gene pharmacogenetic panel predicting response across 34 drugs used in cardiometabolic, gastrointestinal, inflammatory, and other conditions.
- Lab
- GC Genome
- Method
- Real-time PCR
- Specimen
- EDTA whole blood
- TAT
- 10–12 days
Preventive genomics
Telorisk®
Telomere-related risk assessment from peripheral blood.
- Lab
- GC Genome
- Specimen
- EDTA whole blood
5 tests
Consumer Wellness Genomics
Wellness-oriented genomic packages for lifestyle, predisposition, and personal insights.
Wellness genomics
Wellness genomics
Gene2me (54 Wellness Options)
Wellness genomics covering healthcare, dietary, nutrition, fitness, beauty, ancestry, and other options.
- Lab
- GC Genome
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- ~12 business days
Wellness genomics
Gene2me Plus (18 Cancers + 11 Diseases)
SNP array covering selected cancer, common disease, and ophthalmic disease predisposition markers.
- Lab
- GC Genome
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Wellness genomics
GSA Package (Multi-panel Array)
Bundled multi-panel array package including Momcare, Gene2me Plus, MyEyeGene, Skincare, Ancestry, and more.
- Lab
- GC Genome
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Wellness genomics
KidsCare — Genetic Testing for Kids/Teens
Genetic predisposition screening across neuropsychological, dermatological, respiratory, refractive, nutritional, athletic, and chronic-condition markers.
- Lab
- GC Genome
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Wellness genomics
MyEyeGene (5 Ophthalmic Diseases)
Predisposition testing for macular degeneration, glaucoma, retinitis pigmentosa, keratoconus, and severe dry eye syndrome.
- Lab
- GC Genome
- Method
- SNP microarray
- Specimen
- EDTA whole blood
- TAT
- 12–14 days
Need guidance?
Need a test that is not listed?
Tell us the clinical question and specimen type. AC can help confirm the best pathway, sample requirements, and next steps.